Protective effect of compression socks in a marathon runner with a genetic predisposition to thrombophilia due to Factor V Leiden

Phys Sportsmed. 2015 Jul;43(3):324-7. doi: 10.1080/00913847.2015.1043183. Epub 2015 May 4.

Abstract

Introduction: The present case study is an analysis of the effect of compression socks on hemostatic activation following a marathon in a female endurance athlete found to be heterozygous for the coagulation factor V (F5 1691 G>A [Arg>Gln rs6025/560]) risk allele that predisposes one to a genetically inherited disorder of blood clotting, Factor V Leiden.

Methods: Markers for coagulation and fibrinolysis were obtained 24 h prior to (PRE), immediately after (FINISH) and 24 h after (POST) completion of two marathons: the first in which the runner was not wearing compression socks, and the second in which the runner wore compression socks throughout the race.

Results: Compression socks worn during a marathon appeared to lower the overall impact on hemostasis as well as clot formation in this particular athlete as evidenced by lower t-PA (-56%), TAT (-63%) and D-dimer (-30%).

Conclusions: Hemostatic activation may be lower with the use of compression socks, and thus may be effective for preserving hemostasis in endurance athletes at risk.

Keywords: Factor V Leiden; Marathon; compression socks; hemostasis.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antithrombin III
  • Biomarkers / blood
  • Factor V / genetics*
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis
  • Genetic Predisposition to Disease*
  • Hemostasis*
  • Heterozygote
  • Humans
  • Peptide Hydrolases / blood
  • Physical Endurance / physiology*
  • Running / physiology*
  • Stockings, Compression*
  • Thrombophilia / genetics
  • Thrombophilia / physiopathology*
  • Tissue Plasminogen Activator / blood

Substances

  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • antithrombin III-protease complex
  • factor V Leiden
  • fibrin fragment D
  • Antithrombin III
  • Factor V
  • Peptide Hydrolases
  • Tissue Plasminogen Activator

Supplementary concepts

  • Thrombophilia, hereditary